Rafael Ba News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year. Currently, the only potential treatment for this condition is liver transplantation, which is available to very few patients. A first-in-human randomized controlled clinical trial using DIALIVE, a novel liver dialysis device, demonstrated its potential as a disease-modifying therapy and resolved liver failure significantly faster and in a greater p...

The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive Safety of novel liver dialysis device confirmed Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03) Significant improvements in mechanistic biomarkers of how Dialive improves organ function 7 th January 2021 - The ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patient...